2026-2034年全球肺病治疗市场规模、份额、趋势和成长分析报告

预计到 2034 年，肺部疾病治疗市场规模将从 2025 年的 933.4 亿美元达到 1,323.9 亿美元，并预计从 2026 年到 2034 年将以 3.96% 的复合年增长率增长。

受气喘、慢性阻塞性肺病（COPD）、肺纤维化和肺部感染疾病等呼吸系统疾病日益普遍的推动，全球肺部疾病治疗市场正经历稳定成长。空气污染加剧、吸烟习惯、职业危害以及人口老化是导致患者数量显着增加的重要因素。诊断率的提高和早期治疗意识的增强也促进了已开发国家和新兴市场的发展。

药物创新在推动这一市场发展中发挥着至关重要的作用。生物目标、联合治疗和先进吸入给药系统的研发正在改善治疗效果。各国政府和医疗机构加大对呼吸系统健康计画的投入，进一步刺激了对有效疗法的需求。此外，呼吸道感染疾病和病毒感染后併发症的影响也促进了肺部相关药物的研发。

展望未来，精准医疗方法和根据基因资讯及疾病特异性因素量身定制的个人化疗法可望惠及市场。发展中地区医疗保健覆盖范围的扩大以及新药候选药物临床试验的增加将进一步加速市场成长。与数位医疗、远端监测和改进的药物输送系统的融合，有望重塑全球肺部疾病管理的未来。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球肺部疾病治疗市场：依疾病类型划分

• 市场分析、洞察与预测
• 气喘
• 慢性阻塞性肺病（COPD）
• 肺癌
• 其他肺部疾病

第五章 全球肺部疾病治疗市场：依药物类别划分

• 市场分析、洞察与预测
• 皮质类固醇
• 支气管扩张剂
• 祛痰药
• 抗生素
• 其他的

第六章 全球肺病治疗市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第七章 全球肺部疾病治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 亚太其他地区
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • GSK
  • AstraZeneca
  • Boehringer Ingelheim
  • Novartis
  • Mylan
  • Vertex Pharmaceuticals
  • F. Hoffman La Roche
  • Teva Pharmaceuticals
  • Cipla
  • Fibrogen
  • Liminal Biosciences
  • PharmAkea Therapeutics
  • IQVIA
  • Sanofi
  • Bayer

The Lung Disease Therapeutics Market size is expected to reach USD 132.39 Billion in 2034 from USD 93.34 Billion (2025) growing at a CAGR of 3.96% during 2026-2034.

The global lung disease therapeutics market is witnessing steady growth driven by the rising prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and lung infections. Increasing air pollution levels, smoking habits, occupational hazards, and aging populations are significantly contributing to the expanding patient pool. Improved diagnosis rates and growing awareness about early treatment are also supporting market expansion across developed and emerging economies.

Pharmaceutical innovation plays a key role in driving this market forward. The development of targeted biologics, combination therapies, and advanced inhalation delivery systems has enhanced treatment outcomes. Governments and healthcare organizations are investing in respiratory health programs, further boosting demand for effective therapeutics. Additionally, the impact of respiratory infections and post-viral complications has intensified research and funding in lung-related drug development.

Looking ahead, the market is expected to benefit from precision medicine approaches and personalized therapies tailored to genetic and disease-specific factors. Expanding healthcare access in developing regions and increasing clinical trials for novel drug candidates will further accelerate growth. Digital health integration, remote monitoring, and improved drug delivery systems are likely to shape the future of lung disease management globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease Type

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Lung Cancer
• Other Lung Diseases

By Drug Class

• Corticosteroids
• Bronchodilator Medications
• Mucolytics
• Antimicrobial Medications
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Mylan, Vertex Pharmaceuticals, F Hoffman La Roche, Teva Pharmaceuticals, Cipla, Fibrogen, Liminal Biosciences, PharmAkea Therapeutics, IQVIA, Sanofi, Bayer
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LUNG DISEASE THERAPEUTICS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Asthma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Chronic Obstructive Pulmonary Disease (COPD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Other Lung Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LUNG DISEASE THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Bronchodilator Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Mucolytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Antimicrobial Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LUNG DISEASE THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LUNG DISEASE THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Disease Type
  • 7.2.2 By Drug Class
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Disease Type
  • 7.3.2 By Drug Class
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Disease Type
  • 7.4.2 By Drug Class
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Disease Type
  • 7.5.2 By Drug Class
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Disease Type
  • 7.6.2 By Drug Class
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL LUNG DISEASE THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 GSK
  • 9.2.2 AstraZeneca
  • 9.2.3 Boehringer Ingelheim
  • 9.2.4 Novartis
  • 9.2.5 Mylan
  • 9.2.6 Vertex Pharmaceuticals
  • 9.2.7 F. Hoffman La Roche
  • 9.2.8 Teva Pharmaceuticals
  • 9.2.9 Cipla
  • 9.2.10 Fibrogen
  • 9.2.11 Liminal Biosciences
  • 9.2.12 PharmAkea Therapeutics
  • 9.2.13 IQVIA
  • 9.2.14 Sanofi
  • 9.2.15 Bayer